These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 32394639)

  • 1. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
    Bassendine MF; Bridge SH; McCaughan GW; Gorrell MD
    J Diabetes; 2020 Sep; 12(9):649-658. PubMed ID: 32394639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.
    Solerte SB; Di Sabatino A; Galli M; Fiorina P
    Acta Diabetol; 2020 Jul; 57(7):779-783. PubMed ID: 32506195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications.
    Drucker DJ
    Endocr Rev; 2020 Jun; 41(3):. PubMed ID: 32294179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19.
    Chen CF; Chien CH; Yang YP; Chou SJ; Wang ML; Huo TI; Lin CC
    J Chin Med Assoc; 2020 Aug; 83(8):710-711. PubMed ID: 32349031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.
    Stoian AP; Papanas N; Prazny M; Rizvi AA; Rizzo M
    J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):494-496. PubMed ID: 32618198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
    Pitocco D; Tartaglione L; Viti L; Di Leo M; Pontecorvi A; Caputo S
    Diabetes Res Clin Pract; 2020 May; 163():108162. PubMed ID: 32335097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?
    Filardi T; Morano S
    J Endocrinol Invest; 2020 Aug; 43(8):1053-1060. PubMed ID: 32495299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
    Valencia I; Peiró C; Lorenzo Ó; Sánchez-Ferrer CF; Eckel J; Romacho T
    Front Pharmacol; 2020; 11():1161. PubMed ID: 32848769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 and diabetes: Can DPP4 inhibition play a role?
    Iacobellis G
    Diabetes Res Clin Pract; 2020 Apr; 162():108125. PubMed ID: 32224164
    [No Abstract]   [Full Text] [Related]  

  • 10. Sitagliptin: a potential drug for the treatment of COVID-19?
    Bardaweel SK; Hajjo R; Sabbah DA
    Acta Pharm; 2021 Jun; 71(2):175-184. PubMed ID: 33151168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The «moonlighting protein» able to explain the T
    Roncati L; Lusenti B
    Med Hypotheses; 2020 Oct; 143():110087. PubMed ID: 32679426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPP4 inhibition: Preventing SARS-CoV-2 infection and/or progression of COVID-19?
    Strollo R; Pozzilli P
    Diabetes Metab Res Rev; 2020 Nov; 36(8):e3330. PubMed ID: 32336007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling DPP4 Receptor Interactions with SARS-CoV-2 Variants and MERS-CoV: Insights into Pulmonary Disorders via Immunoinformatics and Molecular Dynamics.
    Roy AN; Gupta AM; Banerjee D; Chakrabarti J; Raghavendra PB
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM).
    Mora-Rodríguez JM; Sánchez BG; Bort A; Díaz-Yuste A; Ballester-González R; Arrieta F; Sebastián-Martín A; Díaz-Laviada I
    Life Sci; 2024 Jan; 336():122292. PubMed ID: 38030058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Proteomic Analysis of the Expression of SARS-CoV-2 Receptors in the Gut of Patients with Chronic Enterocolitis.
    Park J; Jeong D; Chung YW; Kim DH; Cheon JH; Ryu JH
    Yonsei Med J; 2020 Oct; 61(10):891-894. PubMed ID: 32975064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
    Dastan F; Abedini A; Shahabi S; Kiani A; Saffaei A; Zare A
    Iran J Allergy Asthma Immunol; 2020 May; 19(S1):10-12. PubMed ID: 32534505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
    Sallenave JM; Guillot L
    Front Immunol; 2020; 11():1229. PubMed ID: 32574272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths.
    Strollo R; Maddaloni E; Dauriz M; Pedone C; Buzzetti R; Pozzilli P
    Diabetes Res Clin Pract; 2021 Jan; 171():108444. PubMed ID: 32946854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus.
    Kleine-Weber H; Schroeder S; Krüger N; Prokscha A; Naim HY; Müller MA; Drosten C; Pöhlmann S; Hoffmann M
    Emerg Microbes Infect; 2020; 9(1):155-168. PubMed ID: 31964246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.